A Phase I-II, Dose-escalation, Double-blinded, Placebo-controlled, and Dose-finding Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Osteoarthritis of the Knee
Latest Information Update: 26 Mar 2024
At a glance
- Drugs 2ccPA (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Orient Europharma
Most Recent Events
- 19 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 13 Apr 2023 New trial record